All In Biotech

Drug Trial Radar · NCT05843643

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE

Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,014 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,014

Actual

Start

Jul 25, 2023

Primary completion

Mar 2027

Study completion Oct 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
May 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 63 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo (does not contain treatment drug) . This study comprised of 4 sub studies. In Study 1 and Study 2, study doctors put the participants in 1 of the 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. Eligible participants from Study 1 and Study 2 will enter Study 3 at week 52 to receive specific doses of upadacitinib. Study 4 is a 104-week continued extension if participation is likely to provide a benefit to their SLE. Approximately 500 participants diagnosed with SLE will be enrolled in each of the Study 1 and Study 2 in approximately 320 sites across the world. Participants will receive oral tablets of upadacitinib or matching placebo once daily for 52 weeks in Study 1 and Study 2. Eligible participants from Study 1 and Study 2 will receive oral tablets of upadacitinib once daily for 52 weeks in Study 3. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • UpadacitinibDrug

    Oral Tablets

  • PlaceboDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving British Isles Lupus Assessment Group Based Combined Lupus Assessment (BICLA) ResponseTime frame: At Week 52

Locations

369 sites in 38 countries. Site status is shown where the registry gives one.

  • AZ Arthritis and Rheumatology /ID# 261848

    Chandler, Arizona

  • AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 254767

    Flagstaff, Arizona

  • Arizona Arthritis & Rheumatology Research, PLLC /ID# 252820

    Gilbert, Arizona

  • Arizona Arthritis and Rheumatology Research - Glendale Office /ID# 252824

    Glendale, Arizona

  • Arizona Arthritis & Rheumatology Research, PLLC /ID# 261845

    Mesa, Arizona

  • Arizona Arthritis & Rheumatology Research /ID# 273555

    Peoria, Arizona

  • Arizona Arthritis & Rheumatology Associates - East Bell Road /ID# 252831

    Phoenix, Arizona

  • Arizona Arthritis & Rheumatology Research, PLLC /ID# 252825

    Phoenix, Arizona

  • HonorHealth Rheumatology /ID# 261953

    Scottsdale, Arizona

  • Arizona Arthritis & Rheumatology Associates - Tucson /ID# 252828

    Tucson, Arizona

  • Arthritis and Rheumatism Associates /ID# 253033

    Jonesboro, Arkansas

  • Kaiser Permanente Lakeview Medical Offices /ID# 253906

    Anaheim, California

  • David S. Hallegua MD, A Professional Corporation /ID# 253902

    Beverly Hills, California

  • Wallace and Lee Center /ID# 275129

    Beverly Hills, California

  • Wallace Rheumatic Studies Center, LLC /ID# 252806

    Beverly Hills, California

  • Advanced Clinical Research Center, LLC dba TriWest Research Associates /ID# 272870

    Chula Vista, California

  • Providence - St. Jude Medical Center /ID# 252822

    Fullerton, California

  • Private Practice - Dr. Chandrakant V. Mehta /ID# 275100

    Hemet, California

  • Newport Huntington Medical Group /ID# 252827

    Huntington Beach, California

  • Moores Cancer Center at UC San Diego /ID# 253903

    La Jolla, California

  • Arthritis & Osteo Medical Ctr /ID# 252812

    La Palma, California

  • Wagdy Kades, M.D., Inc /ID# 272065

    Los Angeles, California

  • Providence St. Johns Health Center /ID# 253905

    Santa Monica, California

  • Millennium Clinical Trials /ID# 252817

    Thousand Oaks, California

  • Cohen Medical Centers /ID# 268524

    Thousand Oaks, California

  • Solace Research /ID# 275198

    Tustin, California

  • Upland Rheumatology Center /ID# 268623

    Upland, California

  • University of Colorado Hospital /ID# 253184

    Aurora, Colorado

  • Denver Arthritis Clinic /ID# 253189

    Denver, Colorado

  • Yale University School of Medicine /ID# 254567

    New Haven, Connecticut

  • Arthritis and Rheumatic Disease Specialties /ID# 253624

    Aventura, Florida

  • HARAC Research Corp. /ID# 254922

    Avon Park, Florida

  • Rheumatology Associates of South Florida (RASF) - Clinical Research /ID# 253623

    Boca Raton, Florida

  • Mdr Core Network, Inc /Id# 276704

    Boynton Beach, Florida

  • Bay Area Arthritis and Osteo /ID# 253597

    Brandon, Florida

  • GNP Consultants, dba, GNP Research /ID# 272868

    Cooper City, Florida

  • Duplicate_Believe Clinical Trials /ID# 255427

    Coral Springs, Florida

  • International Medical Research /ID# 253617

    Daytona Beach, Florida

  • Omega Research Debary, LLC /ID# 254939

    DeBary, Florida

  • University of Florida /ID# 261984

    Gainesville, Florida

Showing 40 of 369 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.